Skip to content

Investing Cash Flow at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$123.1M+173%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
-$121K+64.2%
Biogen logo
BiogenBIIB
-$209.5M-343%
Alkermes logo
AlkermesALKS
-$2.08B-22,919%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
-$506.2M-3,665%
TG Therapeutics logo
TG TherapeuticsTGTX
-$9.86M+23.7%

Other financials

Income statement

See full
Revenue--100%
Operating income-$105.9M-41.7%
Net income-$92.6M-33.6%
EPS (diluted)-$3.20+2.7%

Balance sheet

See full
Cash & equivalents$536.7M+223%
Total debt$1.4M+31.3%
Total equity$1.4B+221%
Total assets$1.5B+205%

Cash flow

See full
Operating cash flow-$86.2M-62.5%
CapEx$62.0K
Free cash flow-$86.2M-62.6%

Valuation

See full
Market cap$7.87B+1,075%
Enterprise value$7.34B+1,309%

Profitability

See full
Operating margin-3,927.5%-1,497pp
Net margin-3,658.5%-1,388pp
FCF margin-3,067.4%-1,030pp

Returns & leverage

See full
Return on equity-35.3%-10.9pp
Debt / equity0.0×
Current ratio15.9×+7.4×

Where this comes from

Reported directly by Praxis Precision Medicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Praxis Precision Medicines, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Praxis Precision Medicines, Inc.'s investing cash flow?
Praxis Precision Medicines, Inc. (PRAX) reported investing cash flow of -$344.28M in Q1 2026.
How has Praxis Precision Medicines, Inc.'s investing cash flow changed year-over-year?
Praxis Precision Medicines, Inc.'s investing cash flow decreased by 574.2% year-over-year, from -$51.06M to -$344.28M.
What does investing cash flow mean?
The net cash flow resulting from the acquisition and disposal of long-term assets and investment securities. It provides insight into how the company allocates capital toward growth or financial instruments.